UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049611
Receipt number R000056128
Scientific Title Evaluation of task-extraction and acceptability of an artificial intelligence decision model for beginning a cancer risk-judgement service
Date of disclosure of the study information 2023/12/01
Last modified on 2022/11/16 10:51:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of task-extraction and acceptability of an artificial intelligence decision model for beginning a cancer risk-judgement service

Acronym

Evaluation of task-extraction and acceptability of an artificial intelligence decision model for beginning a cancer risk-judgement service

Scientific Title

Evaluation of task-extraction and acceptability of an artificial intelligence decision model for beginning a cancer risk-judgement service

Scientific Title:Acronym

Evaluation of task-extraction and acceptability of an artificial intelligence decision model for beginning a cancer risk-judgement service

Region

Japan


Condition

Condition

Healthy male/female adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In order to verify task-extractions and improvement of a cancer risk-decision artificial intelligence model, and an acceptability of the cancer risk-judgement service, for cancer therapy-completed subjects.

Basic objectives2

Others

Basic objectives -Others

In order to verify task-extractions and improvement of a cancer risk-decision artificial intelligence model, and an acceptability of the cancer risk-judgement service, for cancer therapy-completed subjects.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Blood-miRNA analysis, blood biochemical tests, hematologic tests, and Brief-type self-administrated Diet History Questionnaire (BDHQ)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Healthy male/female subjects, not less than twenty years old at informed consent.
(2) Subjects being under the conditions described below:
Suffering from colon cancer, and for the duration of their follow-up period (except anticancer drug therapy) or completed their period.
Suffering from other cancers (except colon one), and for the duration of their follow-up period (except anticancer drug therapy).
(3) Subjects who can give informed consent to take part in this research, after being provided with an explanation of the protocol detail.

Key exclusion criteria

(1) Subjects being under some kind of continuous medical treatment (e.g., diabetes mellitus, heart/liver/kidney/mental disease).
(2) Others who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Ryousuke
Middle name
Last name Matsuoka

Organization

Kewpie Corporation

Division name

General Manager

Zip code

182-0002

Address

Sengawa Kewport 2-5-7 Sengawa-Cho, Chofu, Tokyo 182-0002, Japan

TEL

03-5384-7759

Email

ryosuke_matsuoka@kewpie.co.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Numa

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

103-0021

Address

4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan

TEL

03-6225-9001

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Kewpie Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan

Tel

03-6225-9005

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 09 Month 20 Day

Date of IRB

2022 Year 09 Month 16 Day

Anticipated trial start date

2022 Year 12 Month 01 Day

Last follow-up date

2023 Year 02 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This research is conducted to verify task-extractions and improvement of a cancer risk-decision artificial intelligence model, and an acceptability of the cancer risk-judgement service, for cancer therapy-completed subjects.


Management information

Registered date

2022 Year 11 Month 25 Day

Last modified on

2022 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056128


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name